Lumira co-leads $25 mln financing of Antios Therapeutics

Atlanta-based biopharmaceutical company Antios Therapeutics Inc has raised US$25 million in a Series A financing. The round was led by Canadian life sciences venture capital firm Lumira Ventures and U.S. firm Domain Associates. Other investors, including Fonds de solidarité FTQ, also participated. Lumira Managing Director Beni Rovinski has joined the board. Antios is focused on developing novel antiviral therapies for unmet medical needs. The funds raised will be used to develop ATI-2173, the company's lead oral drug candidate for treating patients infected with Hepatitis B virus and potentially Hepatitis D.

CanadaNorth AmericaBriefs